Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate/testosterone decanoate

Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate/testosterone decanoate (TP/TPP/TiC/TD), sold under the brand name Sustanon 250 (Organon) among others, is an injectable combination medication of four testosterone esters, all of which are androgens/anabolic steroids. They include:

TP/TPP/TiC/TD
Combination of
Testosterone propionateAndrogen; Anabolic steroid
Testosterone phenylpropionateAndrogen; Anabolic steroid
Testosterone isocaproateAndrogen; Anabolic steroid
Testosterone decanoateAndrogen; Anabolic steroid
Clinical data
Trade namesDurandrone Forte, Durateston, Prarbolan, Sustanon 250, Sustanon Prolongatum
Other namesTP/TPP/TiC/TD
Routes of
administration		Intramuscular injection
Identifiers
CAS Number
PubChem CID
ChemSpider

They are provided as an oil solution and are administered by intramuscular injection. The different testosterone esters provide for different elimination half-lives in the body. Esterification of testosterone provides for a sustained but non-linear release of testosterone hormone from the injection depot into the circulation. Sustanon 100 is administered once every 2 weeks and Sustanon 250 is administered once every 3 to 4 weeks.[1]

Sustanon is the preferred method of testosterone replacement in the United Kingdom as detailed in the British National Formulary. There was a brief shortage of Sustanon 250 during late 2011, due to licensing problems,[2] and a further shortage in mid-2012 due to manufacturing problems.

This form of testosterone is a popular choice of anabolic steroid among bodybuilders and athletes.

Androgen replacement therapy formulations and dosages used in men
RouteMedicationMajor brand namesFormDosage
OralTestosteronea–Tablet400–800 mg/day (in divided doses)
Testosterone undecanoateAndriol, JatenzoCapsule40–80 mg/2–4x day (with meals)
MethyltestosteronebAndroid, Metandren, TestredTablet10–50 mg/day
FluoxymesteronebHalotestin, Ora-Testryl, UltandrenTablet5–20 mg/day
MetandienonebDianabolTablet5–15 mg/day
MesterolonebProvironTablet25–150 mg/day
BuccalTestosteroneStriantTablet30 mg 2x/day
MethyltestosteronebMetandren, Oreton MethylTablet5–25 mg/day
SublingualTestosteronebTestoralTablet5–10 mg 1–4x/day
MethyltestosteronebMetandren, Oreton MethylTablet10–30 mg/day
IntranasalTestosteroneNatestoNasal spray11 mg 3x/day
TransdermalTestosteroneAndroGel, Testim, TestoGelGel25–125 mg/day
Androderm, AndroPatch, TestoPatchNon-scrotal patch2.5–15 mg/day
TestodermScrotal patch4–6 mg/day
AxironAxillary solution30–120 mg/day
Androstanolone (DHT)AndractimGel100–250 mg/day
RectalTestosteroneRektandron, TestosteronbSuppository40 mg 2–3x/day
Injection (IM or SC)TestosteroneAndronaq, Sterotate, VirosteroneAqueous suspension10–50 mg 2–3x/week
Testosterone propionatebTestovironOil solution10–50 mg 2–3x/week
Testosterone enanthateDelatestrylOil solution50–250 mg 1x/1–4 weeks
XyostedAuto-injector50–100 mg 1x/week
Testosterone cypionateDepo-TestosteroneOil solution50–250 mg 1x/1–4 weeks
Testosterone isobutyrateAgovirin DepotAqueous suspension50–100 mg 1x/1–2 weeks
Mixed testosterone estersSustanon 100, Sustanon 250Oil solution50–250 mg 1x/2–4 weeks
Testosterone undecanoateAveed, NebidoOil solution750–1,000 mg 1x/10–14 weeks
Testosterone buciclatea–Aqueous suspension600–1,000 mg 1x/12–20 weeks
ImplantTestosteroneTestopelPellet150–1,200 mg/3–6 months
Notes: Men produce about 3 to 11 mg testosterone per day (mean 7 mg/day in young men). Footnotes: a = Never marketed. b = No longer used and/or no longer marketed. Sources: See template.
Medications and dosages used in masculinizing hormone therapy for transgender men
MedicationBrand namesTypeRouteDosage
Testosterone undecanoateAndriol, JatenzoAndrogenOral40–80 mg/2–3x day (with meals)
TestosteroneStriantAndrogenBuccal30 mg 2x/day
NatestoNasal spray11 mg 3x/day
AndroGel, othersTransdermal gel25–100 mg/day
Androderm, othersTransdermal patch2.5–10 mg/day
AxironAxillary solution30–120 mg/day
TestopelSubcutaneous implant150–600 mg/3–6 months
Testosterone enanthateDelatestryl, othersAndrogenInjection (IM or SC)50–100 mg/week or 100–250 mg/2–4 weeks
Testosterone cypionateDepo-Testosterone, othersAndrogenInjection (IM or SC)50–100 mg/week or 100–250 mg/2–4 weeks
Testosterone isobutyrateAgovirin DepotAndrogenInjection (IM or SC)50–100 mg/week
Mixed testosterone estersSustanon 250, othersAndrogenInjection (IM or SC)250 mg/2–3 weeks or 500 mg/3–6 weeks
Testosterone undecanoateAveed, Nebido, othersAndrogenInjection (IM or SC)750–1,000 mg/10–14 weeks
GnRH analogueVariousGnRH modulatorParenteral (various)Variable
ElagolixOrilissaGnRH antagonistOral150 mg/day or 200 mg/twice a day
Medroxyprogesterone acetateaProvera, othersProgestinOral5–10 mg/day
Depo-Provera, othersInjection (IM)150 mg/3 months
Depo-SubQ Provera 104Injection (SC)104 mg/3 months
LynestrenolaOrgametril, othersProgestinOral5–10 mg/day
FinasteridebPropecia, Proscar5α-Reductase inhibitorOral1 mg/day
DutasteridebAvodart5α-Reductase inhibitorOral0.5 mg/day
Notes: Testes produce 3 to 11 mg testosterone per day (mean 7 mg/day in young men). Footnotes: a = For suppression of menses. b = For prevention/treatment of scalp hair loss. Sources: See template.
Androgen replacement therapy formulations and dosages used in women
RouteMedicationMajor brand namesFormDosage
OralTestosterone undecanoateAndriol, JatenzoCapsule40–80 mg 1x/1–2 days
MethyltestosteroneMetandren, EstratestTablet0.5–10 mg/day
FluoxymesteroneHalotestinTablet1–2.5 mg 1x/1–2 days
NormethandroneaGinecosideTablet5 mg/day
TiboloneLivialTablet1.25–2.5 mg/day
Prasterone (DHEA)b–Tablet10–100 mg/day
SublingualMethyltestosteroneMetandrenTablet0.25 mg/day
TransdermalTestosteroneIntrinsaPatch150–300 μg/day
AndroGelGel, cream1–10 mg/day
VaginalPrasterone (DHEA)IntrarosaInsert6.5 mg/day
InjectionTestosterone propionateaTestovironOil solution25 mg 1x/1–2 weeks
Testosterone enanthateDelatestryl, Primodian DepotOil solution25–100 mg 1x/4–6 weeks
Testosterone cypionateDepo-Testosterone, Depo-TestadiolOil solution25–100 mg 1x/4–6 weeks
Testosterone isobutyrateaFemandren M, FolivirinAqueous suspension25–50 mg 1x/4–6 weeks
Mixed testosterone estersClimacteronaOil solution150 mg 1x/4–8 weeks
Omnadren, SustanonOil solution50–100 mg 1x/4–6 weeks
Nandrolone decanoateDeca-DurabolinOil solution25–50 mg 1x/6–12 weeks
Prasterone enanthateaGynodian DepotOil solution200 mg 1x/4–6 weeks
ImplantTestosteroneTestopelPellet50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.
Parenteral durations of androgens/anabolic steroids
MedicationFormMajor brand namesDuration
TestosteroneAqueous suspensionAndronaq, Sterotate, Virosterone2–3 days
Testosterone propionateOil solutionAndroteston, Perandren, Testoviron3–4 days
Testosterone phenylpropionateOil solutionTestolent8 days
Testosterone isobutyrateAqueous suspensionAgovirin Depot, Perandren M14 days
Mixed testosterone estersaOil solutionTriolandren10–20 days
Mixed testosterone estersbOil solutionTestosid Depot14–20 days
Testosterone enanthateOil solutionDelatestryl14–20 days
Testosterone cypionateOil solutionDepovirin14–20 days
Mixed testosterone esterscOil solutionSustanon 25028 days
Testosterone undecanoateOil solutionAveed, Nebido100 days
Testosterone buciclatedAqueous suspension20 Aet-1, CDB-1781e90–120 days
Nandrolone phenylpropionateOil solutionDurabolin10 days
Nandrolone decanoateOil solutionDeca Durabolin21 days
MethandriolAqueous suspensionNotandron, Protandren8 days
Methandriol bisenanthoyl acetateOil solutionNotandron Depot16 days
Metenolone acetateOil solutionPrimobolan3 days
Metenolone enanthateOil solutionPrimobolan Depot14 days
Note: All are via i.m. injection. Footnotes: a = TP, TV, and TUe. b = TP and TKL. c = TP, TPP, TiCa, and TD. d = Studied but never marketed. e = Developmental code names. Sources: See template.

See also

References
  1. William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 392–398. ISBN 978-0-9828280-1-4.
  2. http://www.oxfordshirepct.nhs.uk/professional-resources/prescribing/prescribing-points/documents/PrescribingPointsJuly11Vol206.pdf
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.